Regulation of major histocompatibility complex gene expression in thyroid epithelial cells by methimazole and phenylmethimazole

Cesdio Giuliani, Ines Bucci, Valeria Montani, Dinah S Singer1, Fabrizio Monaco, Leonard D Kohn2 and Giorgio Napolitano

Unit of Endocrinology, Department of Medicine and Sciences of Aging, University ‘G. D’Annunzio’ and Aging Research Center (Ce.S.I.), ‘Gabriele D’Annunzio’ University Foundation, via Colle dell’Ara, Chieti-Pescara, 66013 Chieti, Italy

1Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
2Department of Biomedical Sciences, College of Osteopathic Medicine, Ohio University, Athens, Ohio 45701, USA

(Correspondence should be addressed to C Giuliani; Email: cgiulian@unich.it)

Abstract

Increased expression of major histocompatibility complex (MHC) class-I genes and aberrant expression of MHC class-II genes in thyroid epithelial cells (TECs) are associated with autoimmune thyroid diseases. Previous studies have shown that methimazole (MMI) reduces MHC class-I expression and inhibits interferon-γ (IFN-γ or IFNG as listed in the MGI Database)-induced expression of the MHC class-II genes in TECs. The action of MMI on the MHC class-I genes is transcriptional, but its mechanism has not been investigated previously. In the present study, we show that in Fisher rat thyroid cell line 5 cells, the ability of MMI and its novel derivative phenylmethimazole (C10) to decrease MHC class-I promoter activity is similar to TSH/cAMP suppression of MHC class-I and TSH receptor genes, and involves a 39 bp silencer containing a cAMP response element (CRE)-like site. Furthermore, we show that C10 decreases MHC class-I gene expression to a greater extent than MMI and at 10- to 50-fold lower concentrations. C10 also reduces the IFN-γ-induced increase in the expression of MHC class-I and MHC class-II genes more effectively than MMI. Finally, we show that in comparison to MMI, C10 is a better inhibitor of specific protein–DNA complexes that are formed with a CRE-like element on the MHC class-II promoter. These data support the conclusion that the immunosuppressive mechanism by which MMI and C10 inhibit MHC gene expression mimics ‘normal’ hormonal suppression by TSH/cAMP.

Journal of Endocrinology (2010) 204, 57–66

Introduction

Increased expression of major histocompatibility complex (MHC) class-I molecules and aberrant expression of MHC class-II molecules on nonimmune cells are involved in the pathogenesis of autoimmune diseases. Indeed, the expression of MHC class-I and class-II molecules is increased in pancreatic β islet cells of patients with type 1 diabetes mellitus, in muscle biopsies of patients with inflammatory myopathies, and in thyroid epithelial cells (TECs) from patients with autoimmune thyroid diseases (Bottazzo et al. 1985, Kohn et al. 2000, Davies 2005, Jain et al. 2007, Gono et al. 2009). The importance of MHC class-I gene overexpression in the pathogenesis of autoimmune diseases is suggested by the observation that MHC class-I-deficient mice do not develop autoimmunity in different experimental models, such as those for systemic lupus erythematosus, type 1 diabetes mellitus, and autoimmune blepharitis (Mozes et al. 1993, Serrezete et al. 1994, Chan et al. 1995, Singer et al. 1999). Down-regulation or the absence of MHC class-I gene expression is also considered a hallmark of tissue immune privilege (Ito et al. 2004, 2008).

The involvement of aberrant MHC class-II gene expression in the development of autoimmune thyroid disease has been supported by several clinical and experimental observations. For example, mice immunized with fibroblasts expressing both human TSH receptor (TSHR) and an MHC class-II molecule develop pathological features of Graves’ disease (Shimojo et al. 1996, Arima et al. 2008).

Methimazole (MMI) is widely used to treat Graves’ disease and other forms of primary hyperthyroidism, and several studies have shown that it transcriptionally down-regulates MHC class-I and class-II gene expression in Fisher rat thyroid cell line 5 (FRTL-5) cells (American Type Culture Collection, CRL-8305; Saji et al. 1992b, Singer et al. 1997, Montani et al. 1998b, Kohn et al. 2000). Furthermore, treatment of mice with MMI reduces cell-surface expression of MHC class-I molecules and prevents the development of experimental systemic lupus erythematosus, blepharitis, and experimental autoimmune uveitis (Singer et al. 1994, Chan et al. 1995, Wang et al. 2003).
In previous studies, we have characterized a tautomeric cyclic thione derivative of MMI, phenylmethimazole (compound 10, or C10; Fig. 1), as more potent than MMI in the reduction of MHC expression. In those studies, we used FRTL-5 cells as a nontransformed cell line of rat TECs, which are a widely used model of TEC functions that are relevant to human pathophysiology (Capen 1996, Fukushima et al. 2008). In these cells, we demonstrated that C10 is a powerful anti-inflammatory and immunosuppressive agent, with a greater efficacy than MMI in decreasing constitutive and interferon-γ (IFN-γ or IFNG as listed in the MGI Database)-induced increases in MHC class-I and class-II gene expression (Kohn et al. 2002, Dagia et al. 2004, Harii et al. 2005). Furthermore, in comparison to MMI, C10 reduced to a much greater extent the increases in MHC class-I and class-II gene expression that were dependent on viral infection, Toll-like receptor 3 (TLR3) stimulation, and IFN-γ (Harii et al. 2005).

In the present study, we have investigated the mechanisms of action of MMI and C10 on MHC class-I and class-II gene expression. C10 was more effective than MMI in the transcriptional down-regulation of the expression of these MHC genes and it opposed the effects of IFN-γ better, which is consistent with its suppression of the increased expression of these genes that results from virus- and TLR3-dependent signaling (Harii et al. 2005). We show that this C10 action is mediated by cis-acting elements that are involved in the down-regulation of MHC class-I promoter activity and of MHC class-II gene expression induced by IFN-γ. Thus, C10 is a potent immunosuppressive agent that may have clinical relevance.

Materials and Methods

Materials

C10 was a gift from Interthyr Research Corporation (Marietta, OH, USA; Kohn et al. 2002). MMI was from Sigma–Aldrich Co. Rat recombinant IFN-γ was from Life Technologies Inc., Invitrogen Corp. [α-32P]deoxy-CTP (3000 Ci/nmol) was from MP Biomedicals Europe (Illkirch, France). The source of all other materials was Sigma–Aldrich Co., unless otherwise specified.

Figure 1 Chemical structures of methimazole (MMI) and 5-phenylmethimazole (C10).

**Cell culture**

The F1 subclone of FRTL-5 cells (American Type Culture Collection, CRL-8305) was a gift from Interthyr Research Foundation (Woodinville, WA, USA). These FRTL-5 cells were grown in 6H medium: Coon’s modified Ham’s F-12 medium supplemented with 5% calf serum, 2 mM glutamine, 1 mM nonessential amino acids, and a mixture of six hormones: bovine TSH (1 × 10^{-10} M), insulin (10 μg/ml), cortisol (0-4 ng/ml), transferrin (5 μg/ml), glycyrrhetinic acid (10 ng/ml), and somatostatin (10 ng/ml). The cells were diploid between the 5th and 25th passages, and had all of the functional properties described previously (Ambesi-Impiombato 1986, Saji et al. 1992a,b, Giuliani et al. 1995, 2008, Napolitano et al. 2002). Fresh 6H medium was added every 2–3 days, and the cells were passaged every 7 days. In individual experiments, the cells were shifted to a five-hormone medium, again with 5% calf serum as described above, but without TSH (5H medium).

C10 was prepared as a 200 mM stock solution in dimethylsulfoxide (DMSO) before being used, and then diluted into the medium at 37 °C to the concentrations indicated. The final DMSO concentration was identical in both control and treated samples, and did not in any case exceed 0.5% (vol/vol).

**RNA isolation and northern analyses**

The FRTL-5 cells were grown to 60% confluency in 6H medium, and then maintained in 5H medium (i.e. without TSH) for 6 days. They were then shifted to 6H medium for 24 h before treatments with control vehicle, C10, or MMI for 48 h. RNA was prepared using a RNeasy Mini Kit (Qiagen Inc.), with 20 μg RNA samples run on denaturing agarose gels, capillary blotted on Nytran membranes (Schleicher & Schuell-Whatman, Florham Park, NJ, USA), u.v. cross-linked, and hybridized using QuickHyb hybridization solution (Stratagene, La Jolla, CA, USA) following the manufacturer's protocol. The probes were labeled with [α-32P]dCTP using Ladderton labeling kits (Takara Mirus Bio, Madison, WI, USA). The MHC class-I probe was a 1.0 kb HpaI fragment of the MHC class-I pH 7 clone spanning the entire cDNA insert (Saji et al. 1992b). The β-actin probe was as described previously (Saji et al. 1992a). Quantitation was performed using a BAS 1500 bioimaging analyzer (FUJI Medical Systems USA, Inc., Stamford, CT, USA).

**Flow-cytometric analysis**

The FRTL-5 cells were grown to 60% confluency in 6H medium, and then maintained in 5H medium (i.e. without TSH) for 6 days. They were then shifted to 6H medium for 24 h before treatments with control vehicle, C10, MMI, or IFN-γ for 48 h.

For MHC class-I-molecule analysis, single cell suspensions were prepared and stained as described previously (Saji et al. 1992a, Shimojo et al. 1996, Giuliani et al. 2000, ...
Napolitano et al. 2002); here, a directly FITC monoclonal antibody against the rat MHC class-I molecule was used: FITC-anti-rat RT1A (clone OX-18) (BD Pharmingen, San Jose, CA, USA). The same procedure was followed to evaluate MHC class-II molecules, except using a FITC mouse anti-rat monoclonal antibody to MHC class-II: FITC anti-rat RT1B (clone OX-6) (AbD Serotec, Kidlington, UK).

An isotype-matched control was used for the detection of background fluorescence: FITC mouse IgG1 isotype control (BD Pharmingen).

Plasmids

The luciferase chimeras of the swine MHC class-I (PD1) 5′-flanking region, p(−1100)Luc, p(−203)Luc, and p(−127)Luc, have been described previously (Napolitano et al. 2002). Briefly, different lengths of the 5′-flanking region of the PD1 (Pdsl1 as listed in the MGI Database) gene were inserted into a pGL2 basic vector (Promega Corp.). The flanking regions and the corresponding constructs were named after the number of the base pair at the 5′ end of the +1 bp, with the latter indicating the start of transcription. The −137 bp region of the HLA-DRα gene promoter (Montani et al. 1998a,b) was inserted into the BlgII–HindIII site of the pGL2 basic vector. The sequences of all of the constructs used were confirmed by standard methods (Sanger et al. 1977).

Transfection and luciferase assay

Stable transfectant cells that contained the PD1–luciferase chimeras were obtained using a diethylaminoethyl (DEAE)-dextran procedure (Lopata et al. 1984, Giuliani et al. 1995, Napolitano et al. 2002). Near confluent cells in 6H medium were co-transfected with 20 μg plasmid DNA and 2 μg pMARneo (Clontech BD Biosciences). After 2 days, G418 (Invitrogen) was added to the medium to a final concentration of 400 μg/ml, and after 3 weeks, the G418-resistant colonies were pooled and used.

For the luciferase assay, cells were grown to 60% confluency in 6H medium, and then maintained in 5H medium (i.e. without TSH) for 6 days. They were then shifted to 6H medium for 24 h before treatments with control vehicle, C10, MMI, or IFN-γ, and then purified on 8% native polyacrylamide gels.

Electrophoretic mobility shift assays

DNA probes were created by restriction enzyme treatments of the chimeric luciferase constructs indicated above, and purified from 2% agarose gels using QIAEX (Qiagen Inc.). These were labeled with [α-32P]dCTP using Klenow fragment (New England Biolabs Inc., Ipswich, MA, USA), and then purified on 8% native polyacrylamide gels.

The electrophoretic mobility shift assays (EMSSAs) were performed as described previously (Giuliani et al. 1995, Montani et al. 1998a,b). The binding reactions in low salt and with no detergent included 1-5 fmol [32P]DNA, 3 μg cell extract, and 3 μg poly(dI-dC) in 10 mM Tris–Cl, pH 7-9, 1 mM MgCl2, 1 mM DTT, 1 mM EDTA, and 5% glycerol, in a total volume of 20 μl, with incubations at room temperature for 30 min. Where indicated, unlabeled oligonucleotide competitors or antibodies were added to the binding reactions, followed by incubation with the cell extracts for 20 min before addition of the labeled DNA. The oligonucleotide competitors used were CRE1, spanning base pairs from −127 to −90 of the PD1 gene and containing the CRE-like site (TGACGCGA); nonpalindromic CRE (NPCRE), a derivative oligonucleotide spanning base pairs from −127 to −90 in which the CRE-like element had been mutated to a nonpalindromic substitution (CGACACGA); 5′-CRE, a derivative oligonucleotide spanning base pairs from −127 to −108 and lacking the CRE-like site and the 5′-flanking region; TSHR suppressor element binding protein-1 (TSEP-1), a single-strand luciferase assays were performed using a luciferase assay system (Promega), following the manufacturer’s instructions, and a LUMAT LB 9507 luminometer (EG & G Berthold, Bundoora, Australia). All values were normalized according to total cell protein.

Cell extracts

FRTL-5 cells were grown in the presence of complete 6H medium until 60% confluency, shifted into 5H medium (i.e. no TSH) for 6 days, and then treated as indicated. Cell extracts were prepared using a modification of a previously described protocol (Dignam et al. 1983). Briefly, the cells were washed twice in cold PBS, pH 7-4, scraped, and centrifuged (500 g; 5 min; 4°C). The cell pellet was resuspended in two volumes of Dignam buffer C (25% glycerol, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES–KOH), pH 7-9, 1.5 mM MgCl2, 420 mM NaCl, 0.5 mM dithiothreitol (DTT), 1 μg/ml leupeptin, 1 μg/ml pepstatin, and 0.5 mM phenylmethylsulfonyl fluoride). The final NaCl concentration was adjusted to 420 mM on the basis of the cell pellet volume. The cells were lysed by repeated cycles of freezing and thawing, and then the cell extracts were centrifuged at 100 000 g at 4°C for 20 min. Finally, the supernatants were recovered, aliquoted, and stored at −70°C.

Luciferase assays were performed using a luciferase assay system (Promega), following the manufacturer’s instructions, and a LUMAT LB 9507 luminometer (EG & G Berthold, Bundoora, Australia). All values were normalized according to total cell protein.

Journal of Endocrinology (2010) 204, 57–66

Downloaded from Bioscientifica.com at 11/28/2018 12:22:57PM via free access
oligonucleotide containing one of the TSEP-1 binding sites of the Tshr gene (5’-AAACTACCTCTCAACGCATCCG-3’). The antibodies used were activator transcription factor (ATF)-1 (F1-1, sc-241), ATF2 (C19, sc-187), and CREB binding protein (CBP or CREBBP as listed in the MGI Database) (A-22, sc-369) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Following the incubations, the reaction mixtures were electrophoresed on 4 or 5% native polyacrylamide gels at 160 V in 0.5 or 1x Tris-borate-EDTA buffer at room temperature. The gels were dried and autoradiographed.

Protein determination

Protein concentrations were determined using BCA protein assay kits (Pierce Biotechnology Inc., Rockford, IL, USA), with crystalline BSA as standard.

Statistical analysis

All experiments were repeated at least three times with independent batches of cells. The data are given as means ± S.D. The significance between experimental values was determined by two-way ANOVA, with P<0.05 or better when the data from all of the experiments were considered.

Results

**C10 decreases constitutive MHC class-I gene expression in FRTL-5 cells**

In a previous report, we showed that at a maximally effective concentration of 5 mM, MMI transcriptionally decreased MHC class-I expression in TECs (Saji et al. 1992b).

In the present study, we have analyzed the effects of the MMI derivative C10 on MHC class-I gene expression. The treatment of FRTL-5 cells with C10 resulted in a 66±7% decrease in MHC class-I RNA levels, a greater decrease than that obtained with MMI (45±5%) (Fig. 2A). Importantly, C10 was maximally effective at a concentration 10-fold lower than MMI (0.5 vs 5.0 mM); no further effects were seen at higher C10 concentrations (Fig. 2A). Treatment with solvent alone (0.5% DMSO) did not show any significant effects relative to nontreated cells (Fig. 2A, Cont DMSO versus Cont). Therefore, under all of the following conditions, the control cells were treated with 0.5% DMSO, a concentration equivalent to or lower than that used for the vehicle in treated cells.

The decrease in MHC class-I RNA levels following C10 treatment was accompanied by a decrease in class-I surface molecule expression, as evaluated by flow-cytometric analysis (Fig. 2B). Furthermore, at a concentration of 0.5 mM, C10 significantly decreased cell-surface expression of MHC class-I molecules to a greater degree than that achieved with 5 mM MMI (Fig. 2B).

**MMI and C10 decrease MHC class-I gene promoter activity through a DNA sequence located within 127 bp of the 5’ end of the transcription start site**

The addition of either 5 mM MMI or 0.5 mM C10 to FRTL-5 cells stably transfected with a construct containing the −1100 bp of the extended MHC class-I promoter region ligated to the luciferase reporter gene [p(−1100)Luc] significantly reduced the luciferase activity (Fig. 3A). To map the MMI/C10-responsive element, FRTL-5 cells stably transfected with the 5’ deletion mutants p(−203)Luc and p(−127)Luc (Fig. 3B) were treated with 5 mM MMI or 0.5 mM C10. Both compounds decreased MHC class-I promoter activity in cells transfected with p(−203)Luc and...
levels of p(−1100)Luc were 67.0 ± 7.2 and 48.5 ± 8.7% of control after treatment with MMI and C10 respectively, whereas those of p(−203)Luc were 63.0 ± 5.0 and 43.0 ± 8.0% of control respectively and those of p(−127)Luc were 68.2 ± 9.2 and 48.6 ± 4.5% of control respectively. No further significant decreases were observed after 48 and 72 h of treatment (data not shown). The effects of C10 were concentration dependent, reaching a maximum at 0.5 mM, with no increases in the effects to 5 mM (Fig. 3C). In contrast, the effects of MMI were only significant at 5 mM (Fig. 3C).

These data indicate that the action of MMI and C10 is mediated by a DNA sequence element located between −127 bp and the start of transcription. This region encompasses a previously described silencer element that spans base pairs from −127 to −90 (Fig. 3B, element d), which contains a CRE-like site (Fig. 3B, element e) (Saji et al. 1997, Kirshner et al. 2000).

To identify the DNA–protein complexes associated with the C10/MII-responsive region, EMSAs were performed using a [32P]-labeled probe corresponding to the 5′-flanking region of the PD1 gene between −168 and +1 bp. The EMSAs with extracts derived from nontreated FRTL-5 cells generated a series of complexes, A–E (Fig. 4A, lane 2). As shown previously, TSH treatment of the FRTL-5 cells induced the appearance of two additional complexes, F and G (Fig. 4 A, lane 4). Interestingly, treatment of FRTL-5 cells with both 0.5 mM C10 and 5 mM MMI also induced the appearance of bands F and G (Fig. 4A, lanes 5 and 3). Thus, TSH/cAMP, C10, and MMI all induced the same pattern of bands in EMSAs, suggesting that common complexes are induced by all of these treatments.

The EMSA bands F and G induced by TSH/cAMP treatment of FRTL-5 cells required the CRE sequence contained within the 168 bp segment (Saji et al. 1997, Kirshner et al. 2000). To determine whether the C10-induced complexes similarly depended on the CRE, competition studies were performed using a nonlabeled 38 bp oligonucleotide that spans the MHC class-I CRE. Indeed, the intact CRE (CRE1), but neither a mutant CRE (NPCRE) nor a sequence flanking CRE (5′-CRE), inhibited the formation of the C10-induced bands F and G (Fig. 4B). Thus, the C10-induced complexes, as with the TSH/cAMP-induced complexes, required an intact CRE.

The formation of the F and G complexes was also inhibited by a single-strand oligonucleotide containing one of the TSEP-1 binding sites of the Tshr gene (Fig. 4B, lane 5 versus lane 1) (Napolitano et al. 2000). The same results were obtained using extracts from cells treated with MMI (data not shown).

C10 and MMI reduce the effects of IFN-γ on MHC class-I and class-II gene expression

Previous studies from our laboratory have demonstrated that MMI opposes IFN-γ-mediated induction of the MHC class-I molecule expression in FRTL-5 cells (Saji et al. 1992b).
Therefore, we next examined whether C10 has a similar effect.

FRTL-5 cells stably transfected with the p(−203)Luc class-I promoter, which contains an IFN response element (Fig. 3B), were treated for 36 h in 6H medium containing 100 U/ml IFN-γ without or with 0.5 mM C10 or 5 mM MMI. As shown in Fig. 5A, both C10 and MMI dramatically blocked IFN-γ-dependent activation of the MHC class-I gene promoter. The effect of C10 was greater than that of MMI (33.8±6.2% vs 50.0±4.3% inhibition respectively) at a 10-fold lower concentration.

These results for the class-I promoter activity were confirmed by flow-cytometric analysis of the surface molecule expression (Fig. 5B).

Since IFN-γ induces de novo MHC class-II gene expression that is blocked by MMI (Montani et al. 1998b), we next evaluated the effects of C10 on IFN-γ induction. FRTL-5 cells were treated with 100 U/ml IFN-γ without or with 0.5 mM C10 or 5 mM MMI for 48 h. As shown by flow-cytometric analysis in Fig. 6A, FRTL-5 cells do not normally express MHC class-II molecules on their surface (Fig. 6A, Cont), while IFN-γ treatment induces their appearance (Fig. 6A, IFN). As with MMI, C10 significantly inhibited this IFN-γ effect (Fig. 6A, IFN+C10 and IFN+MMI respectively).

C10 action on the MHC class-II promoter is similar to that of MMI, but its effects are seen at 10- to 50-fold lower concentrations

To determine whether C10 and MMI target MHC class-II gene transcription, FRTL-5 cells were transiently transfected with a construct containing 137 bp of a minimal HLA-DRα promoter (HLA-DRα–Luc) (Balducci-Silano et al. 1998, Montani et al. 1998a,b). The cells were treated for 48 h with 100 U/ml IFN-γ without or with 5 mM MMI or C10 at the concentrations shown in Fig. 6B. In the absence of IFN-γ treatment, the −137 bp HLA-DRα promoter was not active in transiently transfected FRTL-5 cells, relative to the vector control (Fig. 6B, 137 versus pGL2). Treatment of FRTL-5 cells with rat recombinant IFN-γ induced −137 bp HLA-DRα–Luc chimera activity (Fig. 6B, IFN). However, addition of C10 suppressed this IFN-γ effect in a dose-dependent fashion (Fig. 6B, C10). The maximal effect of C10 was seen at 0.5 mM (36.0±9.8% of control), the same concentration that had maximal activity in decreasing MHC class-I gene expression. There were no significant increases in the inhibitory action of C10 at higher concentrations (Fig. 6B, C10, 5 mM).

**Figure 4** Effects of MMI and C10 on binding of proteins to the −168 bp probe. Representative EMSAs performed using cell extracts, as detailed in Materials and Methods, and the −168 bp probe, which spans the region between −168 and +1 bp from the transcription start site of the PD1 gene. (A) FRTL-5 cells were grown and prepared as detailed in Materials and Methods, with final treatments in 5H medium as indicated with 0.5% DMSO (Control), 5 mM MMI, 1×10−10 M TSH, or 0.5 mM C10 for 36 h. Protein–DNA complexes are labeled as A–G (see text). Lane 1, probe alone. (B) FRTL-5 cells were grown and prepared as detailed in Materials and Methods, with the probe incubated in 5H medium with 0.5 mM C10 alone or with 100-fold excess of unlabeled competitors as indicated for 36 h. Protein–DNA complexes are labeled as A–G (see text). Similar results were obtained using cell extracts from cells treated with 5 mM MMI (data not shown).
As consistently seen, C10 was more effective than MMI and its effects were present at 10- to 50-fold lower concentrations (Fig. 6B, C10 versus MMI). The C10 effects were significant after 24 h of treatment (with MHC class-II gene expression being 66.0 ± 4.0% of control cells treated with IFN-γ) and maximal after 48 h (with MHC class-II gene expression being 36.0 ± 9.8% of control cells). To further investigate the mechanism of action of C10 on MHC class-II gene expression, we performed EMSAs using the K137 bp fragment of the HLA-DRα minimal promoter as a radiolabeled probe. As described previously (Montani et al. 1998b), cell extracts from IFN-γ-treated cells (100 U/ml) increased the abundance of a constitutive protein–DNA complex (Fig. 7A, lane 3, band A) and maximal after 48 h (with MHC class-II gene expression being 36.0 ± 9.8% of control cells). The dashed line represents the isotype-matched control.

As consistently seen, C10 was more effective than MMI and its effects were present at 10- to 50-fold lower concentrations (Fig. 6B, C10 versus MMI). The C10 effects were significant after 24 h of treatment (with MHC class-II gene expression being 66.0 ± 4.0% of control cells treated with IFN-γ) and maximal after 48 h (with MHC class-II gene expression being 36.0 ± 9.8% of control cells). To further investigate the mechanism of action of C10 on MHC class-II gene expression, we performed EMSAs using the K137 bp fragment of the HLA-DRα minimal promoter as a radiolabeled probe. As described previously (Montani et al. 1998b), cell extracts from IFN-γ-treated cells (100 U/ml) increased the abundance of a constitutive protein–DNA complex (Fig. 7A, lane 3, band A) and induced the appearance of a new faster migrating complex, (Fig. 7A, lane 3, band B). Treatment of cells with 0.5 mM C10 suppressed the effects of IFN-γ on the formation of both of these complexes (Fig. 7A, lane 5 versus lane 3). C10 was more effective than MMI at a concentration that is 10-fold lower (Fig. 7A, lane 5 versus lane 4).

Pre-incubation of FRTL-5 cell extracts with antibodies against the transcription factors ATF-1, ATF-2, and CBP, as described in Montani et al. (1998b), reduced the abundance of these two protein–DNA complexes (Fig. 7B, lanes 3, 2, and 4 respectively versus lane 1), suggesting a potential

**Figure 5** Effects of C10 and MMI on IFN-γ-induced increase in MHC class-I gene expression. (A) G418-resistant FRTL-5 cells stably transfected with p(−203)Luc were grown and prepared as detailed in Materials and Methods, with final treatments in 6H medium with 0.5% DMSO as vehicle (Cont) or 100 U/ml IFN-γ without or with 0.5 mM C10 or 5 mM MMI as indicated for 36 h. Luciferase activity is expressed as percentages of control activity, with data as means of three separate experiments. *P < 0.05 compared to control; **P < 0.05 compared to IFN. (B) Flow-cytometric analysis of the expression of surface MHC class-I molecules. FRTL-5 cells were grown and prepared as detailed in Materials and Methods, with final treatments in 6H medium as in (A) as indicated for 48 h. The cells were stained with a fluoresceinated monoclonal antibody that specifically reacts with epitope 5 of the rat MHC class-I molecule. The dashed line represents the isotype-matched control.

**Figure 6** Effects of C10 and MMI on IFN-γ-induced MHC class-II molecule expression. (A) Flow-cytometric analysis of the expression of surface MHC class-II molecules. FRTL-5 cells were grown and prepared as detailed in Materials and Methods, with final treatments in 6H medium with 0.5% DMSO as vehicle (Cont) or with 100 U/ml INF-γ without or with 0.5 mM C10 or 5 mM MMI as indicated for 48 h. The cells were stained with a fluoresceinated monoclonal antibody that specifically reacts with RT1B (clone OX-6) of the rat MHC class-II molecule. The dashed line represents the isotype-matched control. (B) Effects of C10 on MHC class-II promoter activity. Transient transfections of FRTL-5 cells with the K137 bp HLA-DRα–Luc chimera were performed as described in Materials and Methods. Twelve hours after transfection, the cells were treated for 48 h with 100 U/ml INF-γ plus 0.5% DMSO as the IFN-induction control (IFN) or with 5 mM MMI or C10 at indicated concentrations. 137: cells transfected with K137 bp HLA-DRα–Luc chimera without 100 U/ml IFN-γ treatment; pGL2: cells transfected with plasmid control vector alone (pGL2 basic) with no further treatment. Luciferase activity is expressed as percentages of IFN-induced activity, with data as means of four separate experiments. *P < 0.05 compared to IFN.
involvement of these transcription factors in the regulation of the MHC class-II gene. Further studies are in progress to evaluate this hypothesis.

**Discussion**

MMI is a thionamide drug that is widely used to treat hyperthyroidism. Its primary effect is to inhibit thyroid hormonogenesis by interfering with the action of the thyroid peroxidase (Cooper 2005a). As well as antithyroid activity, MMI has anti-inflammatory and immunosuppressive effects (Mitsiades et al. 2001, Cooper 2005a, Davies 2005). Although the latter effects have been viewed in the context of MMI action on thyroid hormone synthesis, several studies have suggested direct anti-inflammatory and immunomodulatory effects of MMI. Among other data, it has been shown that MMI inhibits a) the increase of CD69 and Fas ligand expression in T cells and TECs respectively from patients with Graves’ disease; and b) the constitutive and/or IFN-induced increased expression of the MHC class-I and class-II genes and ICAM–I gene in TECs (Weetman et al. 1984, Saji et al. 1992b, Montani et al. 1998b, Kim et al. 2001, Mitsiades et al. 2001, Zantutt-Wittmann et al. 2001, Cooper 2005a, Davies 2005).

In the present study, we have shown that a phenyl derivative of MMI, C10 (Fig. 1), is 10– to 50-fold more potent than MMI at suppressing abnormally increased MHC molecules in TECs. Specifically, using FRTL-5 cells, we have shown that C10 decreases constitutive and IFN-α-induced MHC class-I gene expression. Both C10 and MMI affect MHC class-I promoter activity by targeting a region within 168 bp of transcription initiation. Moreover, we have shown here that these actions of MMI and C10 mimic the actions of TSH/cAMP on MHC class-I gene expression. Indeed, MMI and C10 act on a region that includes the constitutive 38 bp silencer of the MHC class-I promoter, which contains a CRE-like sequence (Saji et al. 1997, Kirshner et al. 2000). Both MMI and C10 induced the formation of two protein–DNA complexes that were not distinguishable in EMSAs from those induced by TSH/cAMP, the formation of which is associated with the down-regulation of the MHC class-I gene induced by TSH/cAMP.

The competition for these two complexes by an oligonucleotide containing a binding site for the Y-box protein TSEP-1 suggests that TSEP-1 is involved in their formation. One hypothesis is that TSEP-1 can interact with other transcription factors, such as CREB, ATF1, and TTF1, which are known regulators of the TSHR and MHC genes in TECs (Saji et al. 1997, Kirshner et al. 2000, Kohn et al. 2000, Napolitano et al. 2000). Further studies are in progress to evaluate this hypothesis and to determine the transcription factors that constitute these complexes.

As already noted above, C10 is more effective than MMI in the regulation of MHC class-I and class-II genes at a concentration that is 10- to 50-fold lower. This is important because MMI anti-inflammatory and immunosuppressive effects are seen at concentrations that exceed those seen in vivo by 10- to 50-fold (Saji et al. 1992b, Cooper 2005b).

These observations are of particular interest given the role that the overexpression of HLA molecules on nonimmune
cells has in the pathogenesis of thyroid autoimmune diseases (Bottazzo et al. 1985, Kohn et al. 2000, Davies 2005, Creus et al. 2009). It has been hypothesized (Harii et al. 2005) that several insults to nonimmune cells of target tissues (such as viral infections, dsRNA, or tissue injury) can activate TLR3 overexpression and signaling, and then induce an innate immune gene response, including secretion of both type 1 (IFN-α or IFN-β) and type 2 (IFN-γ) IFNs. This would result in an overexpression of TLR, MHC molecules, and cytokines by the target cells, which would then recruit and activate lymphocytes and hence initiate an autoimmune response (Kohn et al. 2000, Harii et al. 2005, Gianoukakis et al. 2008, Pitsysky 2008). Given this hypothesis, it is important to stress that both MMI and, to a greater extent, C10 inhibit overexpression of TLR3 molecules and the signaling induced by dsRNA and viruses in TECs (Harii et al. 2005). Indeed, C10 and MMI are strong inhibitors of STAT-1 and STAT-3 phosphorylation (Kim et al. 2001, Harii et al. 2005). Activation of the STAT proteins is one of the mechanisms by which dsDNA and dsRNA activate MHC, IFNs, TLRs, and other related genes (Kohn et al. 2000, Harii et al. 2005).

The mechanisms of action of these compounds explain their broader anti-inflammatory effects and suggest a therapeutic role for C10 beyond thyroid autoimmune diseases (Dagia et al. 2004). We are now carrying out animal studies to investigate these potential therapeutic properties of C10 in vivo. Preliminary results indicate that C10 has potential for autoimmune diseases regardless of thyroid function. Indeed, using Shimojo’s mouse model of Graves’-like disease (Arina et al. 2008), we have found that the administration of C10 can prevent the onset of the disease in the majority of the mice without causing hypothyroidism (Cerrone et al. 2008). Further studies are in progress to confirm these preliminary observations.

In summary, our data show that C10 inhibits constitutive and IFN-γ-induced MHC gene expression in TECs to a greater extent than MMI. Although the effects of MMI on MHC class-I gene expression were reported several years ago, these C10 effects on the MHC genes, together with its action on TLRs and IFN-regulated genes, suggest that it should have a role in the treatment of diseases involving dysfunction of innate immunity. Thus, C10 holds promise as a therapeutic agent for the treatment of autoimmune/inflammatory and other diseases, e.g. cancer, in which the TLR and STAT proteins have pathogenic roles.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicial to the impartiality of the research reported herein.

Funding

Funding for this study was in part through a grant from the nonprofit Interthyr Research Foundation.

Acknowledgements

The authors are grateful to Massimo Ruzzi and Christian Mazzocco for their technical assistance, and to Christopher P Berrie, MA, MPhil, PhD, for linguistic revision of the manuscript. Additionally, the authors would like to acknowledge the anonymous reviewers who have helped them to improve the presentation of their study.

References


www.endocrinology-journals.org

Journal of Endocrinology (2010) 204, 57–66

Downloaded from Bioscientifica.com at 11/28/2018 12:22:57PM via free access


Received in final form 14 October 2009
Accepted 16 October 2009
Made available online as an Accepted Preprint 16 October 2009